ctibiopharma.com | CTI BioPharma | Targeted Blood Cancer Therapies |

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔

Meta Tags

Title	CTI BioPharma \| Targeted Blood Cancer Therapies \|
Description	we start with CTI BioPharma focuses on the acquisition, development and commercialization of therapies for blood-related cancers that offer unique benefits to
Keywords	N/A

Server Information

WebSite	ctibiopharma.com
Host IP	141.193.213.20
Location	United States

Related Websites

                        Site
                        Rank
                    

More to Explore

ctibiopharma.com Valuation

US$42,648,719

Last updated: 2023-05-08 20:14:38

ctibiopharma.com has Semrush global rank of 248,174. ctibiopharma.com has an estimated worth of US$ 42,648,719, based on its estimated Ads revenue. ctibiopharma.com receives approximately 4,921,006 unique visitors each day. Its web server is located in United States, with IP address 141.193.213.20. According to SiteAdvisor, ctibiopharma.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$42,648,719
Daily Ads Revenue	US$39,369
Monthly Ads Revenue	US$1,181,042
Yearly Ads Revenue	US$14,172,498
Daily Unique Visitors	328,068
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
ctibiopharma.com.	A	7199	IP: 141.193.213.20
ctibiopharma.com.	A	7199	IP: 141.193.213.21
ctibiopharma.com.	NS	1800	NS Record: dns101.register.com.
ctibiopharma.com.	NS	1800	NS Record: dns102.register.com.
ctibiopharma.com.	MX	1800	MX Record: 0 mxa-001ecb01.gslb.pphosted.com.
ctibiopharma.com.	MX	1800	MX Record: 0 mxb-001ecb01.gslb.pphosted.com.
ctibiopharma.com.	TXT	1800	TXT Record: MS=ms62423577
ctibiopharma.com.	TXT	1800	TXT Record: google-site-verification=HiWGJmusBeXojma90Sv0jDeDKexPsPog5noupy5upaw
ctibiopharma.com.	TXT	7200	TXT Record: smartsheet-site-validation=D_Ix9sk_uRSkDgbn4WUf64fCW_QBODtP
ctibiopharma.com.	TXT	7200	TXT Record: apple-domain-verification=ikeqzRgHNj5ioLsB
ctibiopharma.com.	TXT	3600	TXT Record: adobe-idp-site-verification=29a851834718dd648891313ebe3f2d76ca640de6ec3c160d8bf99c77c5f935a7
ctibiopharma.com.	TXT	7200	TXT Record: v=spf1 include:spf.protection.outlook.com include:spf.emailsignatures365.com ~all
ctibiopharma.com.	TXT	1800	TXT Record: cDHNlp0ZZLN93ZsmT8rEypMfPUXr/9xUkg9Rva7P0VDexWUqF5qRl58eGsurcgFwawWLa9TJ2qzooVACehCqJw==
ctibiopharma.com.	TXT	1800	TXT Record: docusign=2120c4e5-1350-439c-95cb-bdb610038e8e

HtmlToTextCheckTime:2023-05-08 20:14:38

Company About Us Leadership Partnering Contact Medicines VONJO® (pacritinib) CTI Access Medicine Support Compliance & Transparency Development Development Overview Myelofibrosis Program Clinical Trials Expanded Access Publications & Posters Careers Our Culture Job Openings Diversity & Inclusion Investors & Media Corporate Profile Press Releases Events & Presentations Events Presentations Stock Information Stock Quote & Chart Analyst Coverage Financial Information SEC Filings Annual Report Quarterly Reports Stockholder Meeting Corporate Governance Documents & Charters Management Team Board of Directors Whistleblower Hotline Investor Resources Investor FAQs Investor Email Alerts Contact IR Contact Patient Resources Contact Patient Resources Select Page we start with them CTI develops novel therapies for patients with rare blood-related cancers by uncovering the underlying scientific drivers of their disease. Learn More we start with them CTI develops novel therapies for patients with

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Sat, 30 Oct 2021 15:51:31 GMT
Content-Type: text/html
Connection: keep-alive
Location: http://www.ctibiopharma.com/
CF-Cache-Status: DYNAMIC
Server: cloudflare
CF-RAY: 6a65ce327b7ee1ea-ORD
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400

HTTP/1.1 301 Moved Permanently
Date: Sat, 30 Oct 2021 15:51:31 GMT
Content-Type: text/html
Connection: keep-alive
Location: https://www.ctibiopharma.com/
CF-Cache-Status: DYNAMIC
Server: cloudflare
CF-RAY: 6a65ce334a9c4961-STL
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400

HTTP/2 200 
date: Sat, 30 Oct 2021 15:51:31 GMT
content-type: text/html; charset=UTF-8
vary: Accept-Encoding
vary: Accept-Encoding
link: ; rel="https://api.w.org/"
link: ; rel="alternate"; type="application/json"
link: ; rel=shortlink
x-powered-by: WP Engine
x-cacheable: SHORT
vary: Accept-Encoding,Cookie
cache-control: max-age=600, must-revalidate
x-cache: HIT: 11
x-cache-group: normal
cf-cache-status: DYNAMIC
expect-ct: max-age=604800, report-uri="https://report-uri.cloudflare.com/cdn-cgi/beacon/expect-ct"
server: cloudflare
cf-ray: 6a65ce33ff7b4951-STL
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400, h3-28=":443"; ma=86400, h3-27=":443"; ma=86400

ctibiopharma.com Whois Information

Domain Name: CTIBIOPHARMA.COM
Registry Domain ID: 1838794909_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.register.com
Registrar URL: http://www.register.com
Updated Date: 2020-10-28T16:23:32Z
Creation Date: 2013-12-11T19:16:07Z
Registry Expiry Date: 2021-12-11T19:16:07Z
Registrar: Register.com, Inc.
Registrar IANA ID: 9
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS101.REGISTER.COM
Name Server: DNS102.REGISTER.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-18T02:08:56Z <<<

ctibiopharma.com valuation and analysis